ES2618457T3 - Liposoma transpulmonar para controlar la llegada del fármaco - Google Patents
Liposoma transpulmonar para controlar la llegada del fármaco Download PDFInfo
- Publication number
- ES2618457T3 ES2618457T3 ES08739274.2T ES08739274T ES2618457T3 ES 2618457 T3 ES2618457 T3 ES 2618457T3 ES 08739274 T ES08739274 T ES 08739274T ES 2618457 T3 ES2618457 T3 ES 2618457T3
- Authority
- ES
- Spain
- Prior art keywords
- liposome
- drug
- arrival
- control
- transpulmonary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/10—Vectors comprising a non-peptidic targeting moiety
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Un liposoma para su uso en fármaco terapéutico o administración génica por administración pulmonar, en el que la superficie del liposoma está modificada con un poli(alcohol vinílico) hidrofobizado terminal.
Description
Ejemplo 2 (Ejemplo de referencia)
Preparación de liposoma modificado con quitosano
Se preparó un liposoma modificado con quitosano de la misma manera que en el Ejemplo 1, excepto que se usó quitosano (peso molecular: 150.000, grado de desacetilación: 85 %) en lugar del poli(alcohol vinílico) hidrofobizado
5 terminal. Sin embargo, el diámetro de partícula aumentó mezclando una cantidad igual de una suspensión de liposomas y tampón que contenía quitosano disuelto en el mismo, y por lo tanto se realizó un tratamiento ultrasónico después de mezcla.
Ejemplo de prueba 1
Evaluación del comportamiento intrapulmonar en ratas
10 El liposoma modificado con polímero del Ejemplo 1 o 2 (Ejemplo de referencia) se administró por vía transbronquial ((15,63 µg de CA/rata) a ratas Wistar macho (7 semanas de edad). Cinco horas después de la administración, se calculó la relación residual de dosificación (% de dosis) midiendo la concentración de CA en tejido pulmonar, fluido de lavado broncoalveolar (BALF) y células de lavado broncoalveolar (BALC) usando un espectrofluorómetro (HITACHI F3010). Para comparación, se realizó una prueba de la misma manera a la anteriormente descrita,
15 excepto que se usó un liposoma que no está modificado con un polímero (la composición de membrana y el contenido de CA son los mismos que en el Ejemplo 1) en lugar del liposoma modificado con polímero (Ejemplo comparativo 1). Los resultados se muestran en la Fig. 1.
Como es evidente a partir de los resultados mostrados en la Fig.1, en el liposoma modificado con polímero del Ejemplo 1, se detectó una fluorescencia más fuerte derivada de CA en BALF en comparación con el Ejemplo
20 comparativo 1. Así, se confirmó que el liposoma modificado con polímero del Ejemplo 1 es útil para ejercer una acción farmacológica en la superficie o las células de superficie de tejido pulmonar, ya que son capaces de retenerse en la superficie de tejido pulmonar durante un largo periodo de tiempo.
En el liposoma modificado con polímero del Ejemplo 2 (Ejemplo de referencia), se mostró que se transfirió más liposoma en el tejido pulmonar debido a que se observó una fluorescencia más fuerte derivada de CA en el liposoma
25 modificado con polímero del Ejemplo 2 (Ejemplo de referencia) en comparación con el Ejemplo comparativo 1. Por lo tanto, se reveló que el liposoma modificado con polímero del Ejemplo 2 (Ejemplo de referencia) puede ser transferido de manera eficiente en tejidos pulmonares en un corto tiempo, y así es posible administrar de manera eficiente en tejido pulmonar fármacos que, por ejemplo, no son fácilmente transferidos en el tejido pulmonar.
8
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007090874 | 2007-03-30 | ||
JP2007090874 | 2007-03-30 | ||
PCT/JP2008/056156 WO2008120736A1 (ja) | 2007-03-30 | 2008-03-28 | 薬物送達制御用経肺投与リポソーム |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2618457T3 true ES2618457T3 (es) | 2017-06-21 |
Family
ID=39808316
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES08739274.2T Active ES2618457T3 (es) | 2007-03-30 | 2008-03-28 | Liposoma transpulmonar para controlar la llegada del fármaco |
ES13178179.1T Active ES2643938T3 (es) | 2007-03-30 | 2008-03-28 | Liposoma transpulmonar para controlar la llegada del fármaco |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13178179.1T Active ES2643938T3 (es) | 2007-03-30 | 2008-03-28 | Liposoma transpulmonar para controlar la llegada del fármaco |
Country Status (20)
Country | Link |
---|---|
US (2) | US8658204B2 (es) |
EP (2) | EP2133097B1 (es) |
JP (2) | JP5191478B2 (es) |
KR (2) | KR20140136047A (es) |
CN (2) | CN101646462A (es) |
AR (1) | AR065865A1 (es) |
AU (2) | AU2008233656B2 (es) |
BR (1) | BRPI0809852A2 (es) |
CA (2) | CA2682376C (es) |
CO (1) | CO6260108A2 (es) |
ES (2) | ES2618457T3 (es) |
IL (1) | IL201172A0 (es) |
MX (1) | MX2009010479A (es) |
NZ (1) | NZ579881A (es) |
PH (1) | PH12014502430A1 (es) |
RU (1) | RU2493874C2 (es) |
TW (1) | TW200902085A (es) |
UA (1) | UA100375C2 (es) |
WO (1) | WO2008120736A1 (es) |
ZA (1) | ZA200906742B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5592897B2 (ja) * | 2008-12-26 | 2014-09-17 | サムヤン バイオファーマシューティカルズ コーポレイション | アニオン性薬物含有薬剤学的組成物及びその製造方法 |
JP2011246464A (ja) * | 2010-04-28 | 2011-12-08 | Wakamoto Pharmaceutical Co Ltd | ジクロフェナクナトリウムを封入した後眼部到達用ポリマーコーティングリポソーム |
KR101601035B1 (ko) * | 2013-02-28 | 2016-03-08 | 주식회사 종근당 | 키토산 및 액상결정 형성 물질을 포함하는 유전자 전달용 조성물 |
ES2750608T3 (es) | 2013-07-25 | 2020-03-26 | Exicure Inc | Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico |
ES2725948T3 (es) | 2014-06-04 | 2019-09-30 | Exicure Inc | Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas |
EP3204499A4 (en) | 2014-10-06 | 2018-04-25 | Exicure, Inc. | Anti-tnf compounds |
CN104922068B (zh) * | 2015-05-22 | 2017-10-13 | 江苏凯基生物技术股份有限公司 | 一种Decoy核酸阳离子脂质体载体及其制备方法 |
CN108137694B (zh) | 2015-09-18 | 2022-08-12 | 慕尼黑工业大学 | 整合素αvβ6的配体及其合成和应用 |
US10154947B2 (en) | 2016-01-06 | 2018-12-18 | The Procter & Gamble Company | Antiperspirant composition |
US9732303B2 (en) | 2016-01-06 | 2017-08-15 | The Procter & Gamble Company | Microcapsules formed from phosphate esters and compositions containing same |
US9730867B2 (en) | 2016-01-06 | 2017-08-15 | The Procter & Gamble Company | Methods of forming a slurry with microcapsules formed from phosphate esters |
US20200297867A1 (en) * | 2016-02-01 | 2020-09-24 | Exicure, Inc. | Surface functionalization of liposomes and liposomal spherical nucleic acids (snas) |
AU2017261360A1 (en) | 2016-05-06 | 2018-11-29 | Exicure Operating Company | Liposomal Spherical Nucleic Acid (SNA) constructs presenting Antisense Oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor MRNA |
TWI754659B (zh) * | 2016-08-08 | 2022-02-11 | 台灣微脂體股份有限公司 | 用於製備含有弱酸性劑之微脂體組合物的傳輸載體、方法及套組 |
US11332498B2 (en) | 2017-03-17 | 2022-05-17 | Technische Universitat Munchen | Ligands for integrin αVβ8, synthesis and uses thereof |
WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
TWI734987B (zh) * | 2019-05-23 | 2021-08-01 | 國立陽明交通大學 | 單醣標記之奈米脂質體藥物遞送系統,其製法及其作為藥物靶定遞送載體之應用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5006343A (en) | 1988-12-29 | 1991-04-09 | Benson Bradley J | Pulmonary administration of pharmaceutically active substances |
RU2130771C1 (ru) | 1998-06-01 | 1999-05-27 | Автушенко Сергей Сергеевич | Способ получения липосомальных препаратов |
BR9915462A (pt) * | 1998-11-18 | 2001-12-11 | Univ Florida | Processos para preparação de partìculas dedroga revestidas e as suas formulaçõesfarmacêuticas |
JP2003504321A (ja) * | 1999-07-08 | 2003-02-04 | オーランド・ハン | リポソーム被包カンナビノイドの肺送達 |
US20020012998A1 (en) * | 2000-03-29 | 2002-01-31 | Igor Gonda | Cationic liposomes |
US20030096774A1 (en) * | 2001-11-21 | 2003-05-22 | Igor Gonda | Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
DE10214983A1 (de) | 2002-04-04 | 2004-04-08 | TransMIT Gesellschaft für Technologietransfer mbH | Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen |
EP1506032A1 (en) * | 2002-05-20 | 2005-02-16 | Research Development Foundation | Aerosol drug inhibition of lung metastases |
RU2238091C2 (ru) * | 2002-12-15 | 2004-10-20 | Закрытое акционерное общество "АИП-Наука" | Способ лечения туберкулеза у человека |
JP2007500239A (ja) * | 2003-05-30 | 2007-01-11 | アルザ・コーポレーシヨン | 薬剤の肺投与の方法 |
JP4503953B2 (ja) | 2003-08-11 | 2010-07-14 | テルモ株式会社 | プレフィルドシリンジの製造方法 |
JP4669665B2 (ja) * | 2004-04-12 | 2011-04-13 | 正彦 阿部 | 細胞毒性のないポリカチオン修飾リポソームおよびその製造方法 |
CN100356919C (zh) * | 2004-05-31 | 2007-12-26 | 上海医药工业研究院 | 羟基喜树碱脂质体及其制备方法 |
CA2577336A1 (en) * | 2004-09-15 | 2006-03-23 | Otsuka Pharmaceutical Co., Ltd. | Permucosal composition and method of improving permucosal absorption |
-
2008
- 2008-03-28 JP JP2009507528A patent/JP5191478B2/ja active Active
- 2008-03-28 AU AU2008233656A patent/AU2008233656B2/en not_active Ceased
- 2008-03-28 TW TW097111328A patent/TW200902085A/zh unknown
- 2008-03-28 NZ NZ579881A patent/NZ579881A/xx not_active IP Right Cessation
- 2008-03-28 UA UAA200910942A patent/UA100375C2/ru unknown
- 2008-03-28 EP EP08739274.2A patent/EP2133097B1/en active Active
- 2008-03-28 WO PCT/JP2008/056156 patent/WO2008120736A1/ja active Application Filing
- 2008-03-28 CN CN200880010670A patent/CN101646462A/zh active Pending
- 2008-03-28 MX MX2009010479A patent/MX2009010479A/es active IP Right Grant
- 2008-03-28 ES ES08739274.2T patent/ES2618457T3/es active Active
- 2008-03-28 CA CA2682376A patent/CA2682376C/en not_active Expired - Fee Related
- 2008-03-28 KR KR1020147029191A patent/KR20140136047A/ko not_active Application Discontinuation
- 2008-03-28 CA CA2885621A patent/CA2885621C/en not_active Expired - Fee Related
- 2008-03-28 KR KR1020097021573A patent/KR101476167B1/ko not_active IP Right Cessation
- 2008-03-28 AR ARP080101281A patent/AR065865A1/es unknown
- 2008-03-28 ES ES13178179.1T patent/ES2643938T3/es active Active
- 2008-03-28 RU RU2009140058/15A patent/RU2493874C2/ru not_active IP Right Cessation
- 2008-03-28 EP EP13178179.1A patent/EP2656858B1/en active Active
- 2008-03-28 US US12/593,827 patent/US8658204B2/en not_active Expired - Fee Related
- 2008-03-28 CN CN2013103086090A patent/CN103356482A/zh active Pending
- 2008-03-28 BR BRPI0809852-2A patent/BRPI0809852A2/pt not_active IP Right Cessation
-
2009
- 2009-09-24 IL IL201172A patent/IL201172A0/en unknown
- 2009-09-28 ZA ZA2009/06742A patent/ZA200906742B/en unknown
- 2009-10-30 CO CO09123134A patent/CO6260108A2/es not_active Application Discontinuation
-
2013
- 2013-01-23 JP JP2013010008A patent/JP5674831B2/ja active Active
- 2013-12-17 US US14/108,826 patent/US9750694B2/en active Active
-
2014
- 2014-07-17 AU AU2014204483A patent/AU2014204483A1/en not_active Abandoned
- 2014-10-30 PH PH12014502430A patent/PH12014502430A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2618457T3 (es) | Liposoma transpulmonar para controlar la llegada del fármaco | |
CY1111159T1 (el) | Πυκνα διαλυματα μεθοτρεξατης | |
AU2016208390B2 (en) | Enhanced stability of novel liquid compositions | |
Khairnar et al. | Development of mucoadhesive buccal patch containing aceclofenac: in vitro evaluations | |
AR052153A1 (es) | Composiciones y metodos para la estabilizacion de ingredientes farmaceuticos activos | |
AR062583A1 (es) | Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan | |
EP2570428A3 (en) | Peptide vaccines with Seq ID No: 379 or 376 for cancers expressing tumor-associated antigens | |
JP2006502703A5 (es) | ||
AR050918A1 (es) | Solucion para infusion de dihidropteridinonas estabilizada para el almacenamiento | |
SI2462246T1 (en) | Fast-setting and / or cessation of substantially unchanged delivery of the product | |
ES2535521T3 (es) | Composición farmacéutica | |
JP2020183423A (ja) | 中枢作用性ペプチド誘導体及び医薬組成物 | |
Anjani et al. | Metronidazole nanosuspension loaded dissolving microarray patches: An engineered composite pharmaceutical system for the treatment of skin and soft tissue infection | |
JP4956981B2 (ja) | オキシメタゾリン含有水性組成物 | |
Li et al. | Nitrogen-doped multiwalled carbon nanotubes enhance bone remodeling through immunomodulatory functions | |
CN103237785A (zh) | 增强的经颊药物递送系统和组合物 | |
TW201815410A (zh) | 藥物之經黏膜吸收促進劑 | |
Saha et al. | Formulation development and evaluation of buccal patches of aceclofenac for gingivitis | |
EP2253326B1 (en) | Pharmaceutical composition for transnasal administration | |
De la Serna et al. | Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles | |
TR200601092T1 (tr) | İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar. | |
CN105769821A (zh) | 他克莫司自组装聚合物纳米粒给药系统及其制备方法 | |
Zhang et al. | Morphology of nanostructures and their long-acting properties in vivo for a novel synthetic peptide of gonadotropin-releasing hormone antagonist | |
US20200147224A1 (en) | Composition containing cationic hydroxyethyl cellulose | |
Dixon et al. | Bin1 Regulates CaV1. 2 Channel Clustering in Ventricular Myocytes |